New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
07:24 EDTBMRNBioMarin price target raised to $72 from $65 at Leerink
Leerink raised its price target for BioMarin after increasing its probability of success for BMN-701 to 60% from 30% following yesterday's data. The firm reiterates an Outperform rating on the stock.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
07:53 EDTBMRNLeerink to hold a tour
Subscribe for More Information
November 10, 2014
10:04 EDTBMRNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:02 EDTBMRNBioMarin upgraded to Buy from Neutral at Goldman
Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use